Table 2.
Results of NMA and TMA for Improving Menstrual Frequency
| TMA | NMA | ||||
|---|---|---|---|---|---|
| Study Group | Studies | Participants | Heterogeneity | Effect Estimate (95% CI) | Effect Estimate (95% CrI) |
| Menstrual frequency(a)* | 5 | ||||
| GLP-1 vs MET | 3 | 81 | (P = 0.0005); I2 = 87% | 0.04 (−0.16, 0.24) | 0.04 (−0.14, 0.22) |
| TZD vs MET | 2 | 59 | (P = 0.77); I2 = 0% | −0.01 (−0.11, 0.09) | −0.01 (−0.24, 0.21) |
| MET + GLP-1 vs MET | 2 | 53 | (P = 0.002); I2 = 89% | 0.15 (−0.11, 0.41) | 0.10 (−0.11, 0.30) |
| MET + GLP-1 vs GLP-1 | 2 | 50 | (P = 0.81); I2 = 0% | 0.02 (0.02, 0.02) | 0.06 (−0.15, 0.26) |
| Menstrual frequency(b)** | 5 | ||||
| TZD vs MET | 3 | 139 | (P = 0.22); I2 = 35% | 1.82 (0.76, 4.36) | 1.80 (0.88, 3.67) |
| MET + TZD vs MET | 3 | 204 | (P = 0.80); I2 = 0% | 4.40 (1.95, 9.96) | 3.68 (1.65, 8.20) |
| MET + TZD vs TZD | 1 | 44 | Not applicable | 1.13 (0.30, 4.27) | 2.05 (0.77, 5.42) |
Abbreviations: GLP-1, glucagon-like peptide-1 receptor agonist; MET, metformin; TZD, thiazolidinedione.
*Menstrual frequency(a) is menstrual cycle frequency (cycles per month).
** Menstrual frequency(b) is menstrual recovery.